BR0314089A - Sacarìdeos modificados, conjugados do mesmo e sua fabricação - Google Patents

Sacarìdeos modificados, conjugados do mesmo e sua fabricação

Info

Publication number
BR0314089A
BR0314089A BR0314089-0A BR0314089A BR0314089A BR 0314089 A BR0314089 A BR 0314089A BR 0314089 A BR0314089 A BR 0314089A BR 0314089 A BR0314089 A BR 0314089A
Authority
BR
Brazil
Prior art keywords
conjugates
linker
new
manufacture
modified saccharides
Prior art date
Application number
BR0314089-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Aldo Giannozzi
Francesco Norelli
Paolo Costantino
Giovanni Averani
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Publication of BR0314089A publication Critical patent/BR0314089A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0314089-0A 2002-08-30 2003-09-01 Sacarìdeos modificados, conjugados do mesmo e sua fabricação BR0314089A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture
PCT/IB2003/004194 WO2004019992A1 (en) 2002-08-30 2003-09-01 Modified saccharides, conjugates thereof, and their manufacture

Publications (1)

Publication Number Publication Date
BR0314089A true BR0314089A (pt) 2005-11-16

Family

ID=9943241

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314089-0A BR0314089A (pt) 2002-08-30 2003-09-01 Sacarìdeos modificados, conjugados do mesmo e sua fabricação

Country Status (16)

Country Link
US (2) US8895516B2 (2)
EP (1) EP1534342B1 (2)
JP (2) JP5268222B2 (2)
CN (2) CN101863998B (2)
AT (1) ATE319481T1 (2)
AU (1) AU2003260921B2 (2)
BR (1) BR0314089A (2)
CA (1) CA2497167C (2)
DE (1) DE60303961T2 (2)
DK (1) DK1534342T3 (2)
ES (1) ES2260682T3 (2)
GB (1) GB0220198D0 (2)
MX (1) MXPA05002315A (2)
NZ (1) NZ538703A (2)
RU (2) RU2005108992A (2)
WO (1) WO2004019992A1 (2)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
WO2005051429A2 (en) * 2003-11-19 2005-06-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeted conjugates with a modified saccharide linker
MX2007013881A (es) 2005-05-06 2008-10-22 Novartis Vaccines & Diagnostic Inmunogenos para vacunas de meningitides-a.
KR101515078B1 (ko) * 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
WO2010027499A2 (en) 2008-09-05 2010-03-11 University Of Massachusetts Medical School Methods, compositions and vaccines relating to neisseria meningitidis antibodies
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
HUE034251T2 (en) * 2009-10-30 2018-02-28 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
ES2701169T3 (es) * 2014-02-14 2019-02-21 Pfizer Conjugados glucoproteicos inmunogénicos
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016170186A1 (en) * 2015-04-23 2016-10-27 Synaffix B.V. PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE
JP2019508468A (ja) * 2016-03-15 2019-03-28 エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドMsd Wellcome Trust Hilleman Laboratories Pvt.Ltd. 新規の多糖体−タンパク質コンジュゲート及びそれを得る方法
BR112019003992A2 (pt) 2016-09-02 2019-05-28 Sanofi Pasteur Inc vacina contra neisseria meningitidis
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7680185B2 (ja) * 2017-02-24 2025-05-20 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎連鎖球菌多糖-タンパク質コンジュゲートの免疫原性の増強
MX394768B (es) 2017-09-07 2025-03-21 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.
MX394767B (es) 2017-09-07 2025-03-24 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
WO2020182635A1 (en) * 2019-03-08 2020-09-17 Glaxosmithkline Biologicals Sa Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427341A1 (fr) * 1978-06-02 1979-12-28 Delalande Sa Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
DK0447171T3 (da) * 1990-03-15 1994-12-12 Tanabe Seiyaku Co Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf
US5698526A (en) * 1993-12-28 1997-12-16 Pfizer Inc. Steroidal glycosides
WO1995029927A2 (en) * 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
US6472506B1 (en) * 1997-01-21 2002-10-29 Aventis Pasteur S.A. Polysaccharide-peptide-conjugates
US5929049A (en) 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
JP4182269B2 (ja) * 1997-08-08 2008-11-19 ベーリングウエルケ、アクティエンゲゼルシャフト 生体分子のポリサッカライド接合体
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers
ES2616180T3 (es) 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture

Also Published As

Publication number Publication date
WO2004019992A1 (en) 2004-03-11
CA2497167A1 (en) 2004-03-11
CN101863998A (zh) 2010-10-20
EP1534342B1 (en) 2006-03-08
CN1688343A (zh) 2005-10-26
NZ538703A (en) 2006-09-29
JP5268222B2 (ja) 2013-08-21
JP5314745B2 (ja) 2013-10-16
EP1534342A1 (en) 2005-06-01
AU2003260921A1 (en) 2004-03-19
MXPA05002315A (es) 2005-06-08
CA2497167C (en) 2011-07-12
DK1534342T3 (da) 2006-07-10
CN1688343B (zh) 2010-09-08
DE60303961D1 (de) 2006-05-04
CN101863998B (zh) 2012-08-29
DE60303961T2 (de) 2006-10-26
JP2006511465A (ja) 2006-04-06
AU2003260921B2 (en) 2008-03-06
US8895516B2 (en) 2014-11-25
RU2008150551A (ru) 2010-06-27
ES2260682T3 (es) 2006-11-01
US20150166593A1 (en) 2015-06-18
GB0220198D0 (en) 2002-10-09
US20060263390A1 (en) 2006-11-23
ATE319481T1 (de) 2006-03-15
RU2005108992A (ru) 2005-11-10
RU2531909C2 (ru) 2014-10-27
JP2012017342A (ja) 2012-01-26

Similar Documents

Publication Publication Date Title
BR0314089A (pt) Sacarìdeos modificados, conjugados do mesmo e sua fabricação
ATE409048T1 (de) Pharmazeutisch aktive oligosaccharid-conjugate
RU2412944C2 (ru) Иммуногены для вакцин против менингита а
WO2005030258A3 (en) Small molecule compositions and methods for increasing drug efficiency using compositions thereof
UY26815A1 (es) Métodos para tratar enfermedades reumáticas al usar una molécula ctla4 soluble
JP2005532287A5 (2)
PL410219A1 (pl) Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
UA95237C2 (uk) Імуногенна композиція
MXPA03011681A (es) Uso de inhibidores de epoxido hidrolasa soluble, para tratar enfermedades relacionadas con la enfermedad cardiovascular.
MEP24608A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
CY1109441T1 (el) Ενδιαμεσα προϊοντα για την παραγωγη διοξανιου-2-αλκυλκαρβαμικου
DK1327146T3 (da) Forbindelse med et forgrenet linkermolekyle
ATE306261T1 (de) Antithrombosemittel
EA200300937A1 (ru) Оральная фармацевтическая композиция цефподоксима проксетила
DK0751144T3 (da) Nye antracyclin-pro-drugs, fremgangsmåde til fremstilling deraf samt antitumorsammensætninger og et komponentkit indeholdende disse pro-drugs
DE602005020608D1 (de) NEISSERIA MENINGITIDIS IgtB LOS ALS ADJUVANS
DK0989972T3 (da) Farmaceutiske prostaglandinsammensætninger
EP1775289A4 (en) NEW IMIDAZOLIDINE DERIVATIVES
CA2423007A1 (en) Spiro derivatives and adhesion molecule inhibitors containing the same as effective ingredients
GB0501964D0 (en) Chemical compounds
EP1996217A4 (en) NOVEL ANTIBIOTIC COMPOSITIONS
EA201070536A1 (ru) Ретиноидное пролекарственное соединение
WO2001079170A3 (en) Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
DK1250335T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af imidazopyridiner

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, S.R.L. (IT)

Free format text: ALTERADO DE: CHIRON SRL.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07H 13/12 (2006.01), A61K 47/64 (2017.01)

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/715 (2006.01), A61K 47/64 (2017.01), C07H

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements